Text Size

Glycosaminoglycans During Septic Shock - a Temporal Study (GAGS)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2009 by Region Skane.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Region Skane
ClinicalTrials.gov Identifier:
NCT00814112
First received: December 22, 2008
Last updated: October 7, 2009
Last verified: October 2009
History of Changes
  Purpose

We have previously shown that the plasma level of glycosaminoglycans (GAG) in septic shock patients are elevated compared to controls. The purpose of this study is to investigate the temporal dynamic of the blood level of GAG in ten septic shock patients. In addition, to assess the kinetics of GAG during septic shock we examine the liver function by galactose elimination capacity as well as excreted urinary GAG.


Condition
Septic Shock

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: GAGS - Glykosaminoglykaner Vid Sepsis

Resource links provided by NLM:

MedlinePlus related topics: Sepsis Shock
U.S. FDA Resources

Further study details as provided by Region Skane:

Biospecimen Retention:   Samples Without DNA

Plasma and Urine.


Estimated Enrollment: 20
Study Start Date: November 2008
Estimated Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
1 septic shock
septic shock, ICU
2 controls
matched controls

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Septic Shock

Criteria

Inclusion Criteria:

  • 2 out of 4 SIRS criteria, where the circulatory criteria must be fulfilled
  • Clinical sepsis is suspected
  • Informed consent from relative
  • Study subject must be over 18 years old

Exclusion Criteria:

  • Pregnancy
  • >24h post sepsis diagnosis
  • Ongoing oral or intravenous cortisone treatment for more than one month.
  • Malignancy with metastasis
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00814112

Contacts
Contact: Ingrid Berkestedt, MD PhD +4646171949 ingrid.berkestedt@skane.se
Contact: Axel Nelson, PhD-student axel.nelson@med.lu.se

Locations
Sweden
Intensive Care Unit, Lund University Hospital Recruiting
Lund, Sweden, 22185
Contact: Ingrid Berkestedt, MD PhD     +4646171949     ingrid.berkestedt@skane.se    
Sub-Investigator: Axel Nelson, PhD student            
Sub-Investigator: Ingrid Berkestedt, MD PhD            
Sponsors and Collaborators
Region Skane
Investigators
Principal Investigator: Mikael Bodelsson, professor Intensive Care Unit, Lund University Hospital, Sweden
  More Information

No publications provided

Responsible Party: Mikael Bodelsson/Professor, Lund University Hospital
ClinicalTrials.gov Identifier: NCT00814112     History of Changes
Other Study ID Numbers: GAGS 293/2008
Study First Received: December 22, 2008
Last Updated: October 7, 2009
Health Authority: Sweden: Regional Ethical Review Board

Additional relevant MeSH terms:
Shock
Shock, Septic
Pathologic Processes
Sepsis
 Infection
Systemic Inflammatory Response Syndrome
Inflammation

ClinicalTrials.gov processed this record on May 22, 2013